Parenteral busulfan: Is therapeutic monitoring still warranted?

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 9, 2002, Pages 465-467

  Grochow, Louise B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; FLUDARABINE; LIPID; LIPOSOME; MACROGOL 400; N,N DIMETHYLACETAMIDE; SPARTAJECT BUSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG FORMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER VEIN OBSTRUCTION; MUCOSA INFLAMMATION; NOTE; SEIZURE; VOMITING; WHOLE BODY RADIATION; CHEMICALLY INDUCED DISORDER; DRUG MONITORING; INFUSION; METHODOLOGY;

BONE MARROW TRANSPLANTATION; BUSULFAN; DRUG MONITORING; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFUSIONS, PARENTERAL; LEUKEMIA, MYELOID, CHRONIC;

EID: 0036401557     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12374450     Document Type: Note

References (16)

1. Haddow A, Timmis G. Myleran in chronic myeloid leukemia. Lancet. 1953;1:207.
2. Santos G, Tutschka P, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-1353.
3. DeLeve L, Shulman H, McDonald G. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27-42.
4. Grochow L, Jones R, Brundrett R, et al. Pharmacokinetics and busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
5. Bearman S. Avoiding hepatic veno-occlusive disease: what do we know and where are we going? Bone Marrow Transplant. 2001;27: 1113-1120.
6. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood. 1994;84:2144-2150.
7. Bhagwatwar H, Phadungponja S, Chow D, et al. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996;37:401-408.
8. Hassan Z, Ljungman P, Ringden O, et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant. 2001;27: 479-485.
9. Olavarria E, Hassan M, Eades A, et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia. 2000;14:1954-1959.
10. Russell J, Tran H, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;9:468-476.
11. Andersson B, Thall P, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;9:477-485.
12. Fernandez H, Tran H, Albrecht F, et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule in patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant. 2002;9:486-492.
13. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hemtopoietic stem cell transplantation: decreased incidence of hepatic veno-occlusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;9:493-5OO.
14. Slattery J, Sanders J, Buckner C, et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant, 1995;16:31-42.
15. Shaw P, Scharping C, Brian R, Earl J. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood. 1994;84:2357-2362.
16. Bleyzac N, Souillet G, Pagron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751.